Slow Subcutaneous Release of Glatiramer Acetate or CD40-Targeting Peptide KGYY<sub>6</sub> Is More Advantageous in Treating Ongoing Experimental Autoimmune Encephalomyelitis
Background/Objectives: One of the first-line disease-modifying treatments of multiple sclerosis (MS) is Glatiramer Acetate (GA), which requires daily or three-times-weekly subcutaneous injections. Disease progression, while slowed, still occurs with time. Increasing the impact of the treatment while...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Neurology International |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2035-8377/16/6/114 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|